177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer;Therapie mit 177Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrations - Resistenten Prostatakarzinom

NuklearMedizin

Volumn 55, Issue 3, 2016, Pages 123-128

  Fendler, Wolfgang P ^a   Kratochwil, Clemens ^b   Ahmadzadehfar, Hojjat ^c   Rahbar, Kambiz ^d   Baum, Richard P ^e   Schmidt, Matthias ^f   Pfestroff, Andreas ^g   Lützen, Ulf ^h   Prasad, Vikas ⁱ   Heinzel, Alexander ^j   Heuschkel, Martin ^k   Ruf, Juri ^l   Bartenstein, Peter ^a   Krause, Bernd J ^m  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e ZENTRALKLINIK BAD BERKA   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g UNIVERSITY HOSPITAL MARBURG   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^k UNIVERSITY OF ROSTOCK   (Germany)

^l UNIVERSITY OF FREIBURG   (Germany)

^m Deutsche Gesellschaft für Rechtsmedizin e V DGRM   (Germany)

more..

Author keywords

Consensus; Lutetium; Prostate cancer; PSMA; Radioligand therapy

Indexed keywords

LUTETIUM 177; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN 617; UNCLASSIFIED DRUG; 177LU-PSMA-617; DIPEPTIDE; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS;

ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; COMPASSIONATE USE; CONSENSUS DEVELOPMENT; DOSIMETRY; DRUG INDICATION; FOLLOW UP; HUMAN; MALE; MEDICAL SOCIETY; MEDICAL STAFF; METASTASIS; STANDARDIZATION; GERMANY; NUCLEAR MEDICINE; PRACTICE GUIDELINE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIATION DOSE; RADIOMETRY; SECONDARY; STANDARDS; TREATMENT OUTCOME;

DIPEPTIDES; FOLLOW-UP STUDIES; GERMANY; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; NUCLEAR MEDICINE; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84976576974     PISSN: 00295566     EISSN: 25676407     Source Type: Journal    
DOI: 10.1055/s-0037-1616480     Document Type: Article

References (24)

1. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Konsultationsfassung: Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 2.2, [2014] AWMF Registernummer: 034/022OL, http://leitlinienprogrammonkologie. de/Leitlinien.7.0.html
2. Deutsche Gesellschaft für Nuklearmedizin e.V., www.nuklearmedizin.de/docs/Lu-177-PSMA_160224.pdf, abgerufen am 16.03.2016.
3. AG RP. Fachinformation ROTOP-Samarium. 2012
4. Block GA, Bone HG, Fang L et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27: 1471-1479.
5. 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008; 35: 1847-1856.
6. Bodei L, Mueller-Brand J, Baum RP et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013; 40: 800-816.
7. Bundesministerium für Umwelt NuR. Strahlenschutz in der Medizin, Richtlinie zur Verordnung über den Schutz vor Schäden durch ionisierende Strahlen (Strahlenschutzverordnung - StrlSchV). RS II 4 - 11432/1.
8. Delker A, Fendler WP, Kratochwil C et al. Dosimetry for Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2015; 43: 42-51.
9. Emami B, Lyman J, Brown A et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21: 109-122.
10. Gensheimer MF, Liao JJ, Garden AS et al. Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes. Radiat Oncol 2014; 9: 255.
11. Hey J, Setz J, Gerlach R et al. Parotid gland-recovery after radiotherapy in the head and neck region--36 months follow-up of a prospective clinical study. Radiat Oncol 2011; 6: 125.
12. 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 1976-1983.
13. Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102: 39-46.
14. 177Lu]Lutetium- labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 987-988.
15. 177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003; 30: 417-422.
16. Miller K, Albers P, Eichenauer R et al. Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring. Urologe A 2014; 53: 710-714.
17. Mottet N, Bellmunt J, Briers E et al. Guidelines on Prostate Cancer. European Association of Urology 2015.
18. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223.
19. Poeppel TD, Boy C, Bockisch A et al. Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1). Nuklearmedizin 2015; 54: 1-11.
20. Robert Koch-Institut dGdeKiDeV. Krebs in Deutschland 2007/2008, 8. Ausg. 2012.
21. th ESMO - European Cancer Congress 2015, 27 September 2015, abstract 6LBA.
22. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
23. Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 2009; 4: 221-233.
24. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20: 2453-2463.